STK25 enhances hepatocellular carcinoma progression through the STRN/AMPK/ACC1 pathway.

Yichao ZhangJunhui XuZhendong QiuYongjun GuanXiaoYi ZhangXin ZhangDongqi ChaiChen ChenQinyong HuWei Xing Wang

Published in: Cancer cell international (2022)

Our results demonstrated that STK25 interacted with STRN to regulates the energy reserve and EMT via lipid metabolism reprogramming. Accordingly, high expression of STK25 may be associated with HCC patients and poor prognosis, which implicates STK25 could be a potential target for lipid metabolism in cancer therapy.

Keyphrases

poor prognosis
long non coding rna
cancer therapy
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
skeletal muscle
peritoneal dialysis
prognostic factors
drug delivery
fatty acid
protein kinase